Medable Newsroom
New Tufts CSDD Analysis Finds AI Agents Can Deliver Up to $21 Million in Net Financial Value Per Drug Development Program and Up to 82x ROI
Medable Inc., the leading technology platform for agentic clinical development, today announced a new Tufts Center for the Study of Drug Development (CSDD) analysis showing that an AI clinical monitoring agent can deliver net financial gains as high as $21 million per drug development program and 82 times the return on investment.
Releases
New Tufts CSDD Analysis Finds AI Agents Can Deliver Up to $21 Million in Net Financial Value Per Drug Development Program and Up to 82x ROI
Medable Inc., the leading technology platform for agentic clinical development, today announced a new Tufts Center for the Study of Drug Development (CSDD) analysis showing that an AI clinical monitoring agent can deliver net financial gains as high as $21 million per drug development program and 82 times the return on investment.
Medable Introduces Digital Data Flow Agent, Laying the Foundation for End-to-End Agentic Clinical Development
Medable introduces its Digital Data Flow Agent, transforming clinical trial protocols into machine-readable data to support adaptive, real-time clinical development.
Medable Launches Agentic Accelerator Program to Help Life Sciences Companies Deploy Agentic AI Across Clinical Development Lifecycle
High-touch enablement helps sponsors operationalize industry-specific agents to realize value faster.
Medable Introduces AI Agent to Reduce Burden at Research Sites by Assisting Principal Investigators with Oversight of eCOA Data
Medable Inc., the leading technology platform for AI-powered clinical development, today announced the launch of Agentic AI for research sites to reduce burden and assist principal investigators in oversight and monitoring of eCOA data.
Medable Debuts AI Agent for Automating Trial Master File (TMF) Processes
TMF Agent significantly improves quality and consistency while drastically reducing the manual effort in document management. It is built on Medable’s Agent Studio, the industry’s first agentic AI platform for clinical development.
Medable Launches Innovation Evidence Workshop – First Collaboration To Bring Leaders Together on DCT Impact, Adoption, and Best Practices
Medable, the leading provider of AI-powered clinical trial technology, today announced its Innovation Evidence Workshop series, developed in collaboration with and facilitated by the Tufts Center for the Study of Drug Development (Tufts CSDD). Leaders from 20 pharmaceutical, biotech, and contract research organizations (CROs) participated in the inaugural invitation-only workshop held on November 19 in Boston, MA. Programming featured representatives from the U.S. Food and Drug Administration, global pharmaceutical companies, leading contract research organizations (CROs), Harvard MRCT, Tufts CSDD, and Medable.
Medable Named a Leader Amid Growing eCOA Adoption
Everest Group’s 2025 Life Sciences eCOA PEAK Matrix® Assessment highlights Medable eCOA leadership in ease of use, AI innovation, and patient-centered design
.webp)
Medable Launches The Industry’s First Agentic AI Platform and CRA Agent; Removes Bottlenecks in Clinical Development
Agent Studio marks a turning point in clinical research, moving from human-heavy processes to scalable agents that streamline work and accelerate trials
Medable Launches Partner Program for Faster Clinical Trial Startup, Greater Control, and Transparent Pricing
Medable unveils its new Partner Program, designed to empower contract research organizations (CROs) and other partners with generative AI-driven, self-service eCOA build capabilities for digitally enabled clinical trials.